·¬ΗΡΙηΗψapp

Meeting Coverage

ASRS

American Society of Retina Specialists

Mixed Results With Senolytic Agent for Retinal Disease

Positive outcome with UBX-1325 in diabetic macular edema but not wet AMD

ASRS over a photo of The Washington State Convention and Trade Center, in Seattle, Washington.

Latest ASRS Meeting Coverage

Early Enthusiasm for Cancer Drug Reformulated for Ophthalmic Use

AMD treatment burden reduced by 80-90% by implant, intrachoroidal axitinib

August 2, 2023
Sticker Shock: Ophthalmic Bevacizumab Biosimilar Could Drive Up Costs

Medicare expenditures could jump 15-30%, with similar increases in patients' out-of-pocket costs

August 1, 2023
Studies Examine Links Between Diabetes and Eye Disease, Treatment, Adverse Events

Anti-VEGF therapy raises risk of systemic events; retinal effects of diabetes drugs differ

July 31, 2023
Pegcetacoplan-Related Eye Inflammation: The Search Is on for Answers

More than a half dozen reports in the last month point to no clear etiology

July 31, 2023
Durable Vision Improvement With Light Therapy for Dry Macular Degeneration

Also from ASRS: gene therapy for retinitis pigmentosa, anti-VEGF implant matches injection

July 20, 2022
Brolucizumab Prevails in Treat-and-Extend Trial of Anti-VEGF Therapy for Eye Disease

Longer treatment-free interval with similar vision outcomes versus aflibercept in neovascular AMD

July 19, 2022
Intravitreal Methotrexate Reduces Reoperation After Retinal Detachment Repair

Reoperation rate reduced by three fourths, use expanded to advanced diabetic retinopathy

July 18, 2022
Link Between Neovascular Eye Disease, CVD Tracked to Retinal Lesions

Subretinal drusenoid deposits found in 85% of patients with AMD and CVD in small study

July 16, 2022
Gene Therapy Shows Promise for Age-Related Macular Degeneration

Reduced treatment burden, durable therapeutic effects with aflibercept-expressing construct

July 15, 2022
'Senolytic' Therapy Shows Promise in Neovascular Eye Disease

Clearing out dying cells, approach has implications far beyond ophthalmology

July 14, 2022
C5 Inhibitor Slows Geographic Atrophy in Dry Macular Degeneration

Progression slowed by 27-30% at 12 and 18 months with avacincaptad versus sham control

October 13, 2021
Bispecific Antibody Compares Favorably With Anti-VEGF for Retinal Disease

Similar visual acuity and safety with potential for extended dosing interval

October 13, 2021
Continuous-Release Anti-VEGF for Macular Degeneration Continues to Impress

Implant matches monthly injections for efficacy with 6-month refill schedule

October 13, 2021
Adverse Events Halt Gene Therapy Trial for Diabetic Macular Edema

Three cases of irreversible vision loss, high rate of intraocular inflammation

October 12, 2021

Videos

ASRS Video Pearls
August 2023